Compelling experimental evidence indicates that reactive oxygen species (ROS) play an important pathophysiological role in the development of cardiovascular diseases (CVDs). This is due, in large part, to .O₂^- excess and decreased NO bioavailability in the vasculature and to ROS-mediated cardiovascular remodelling. To date, although the common pharmacological therapy with statins, antihypertensives, and anti-inflammatory drugs has reduced over 50% of the mortality for cardiovascular events, their potential role as modulators of vascular oxidative stress is currently an area of active research. Moreover, although, in the last decade, accumulating evidence has highlighted the potential effects of the natural-derived compound to reduce the oxidative stress and to protect against the progression of cardiovascular diseases, the identification of the molecular mechanisms of intracellular signalling remains to be elucidated.

Based on these data, we invite investigators to contribute original research as well as review articles on the antioxidant vascular effects of different pharmacological and nonpharmacological approaches to prevent and fight the development of cardiovascular diseases.

We are focused on articles describing new mechanisms, new molecules, and new approaches to regulate oxidative stress in cardiovascular diseases.

Potential topics include but are not limited to the following:

• In vitro and in vivo studies on the role of oxidative stress in endothelial dysfunction: pharmacological and nonpharmacological approaches
• How ROS regulate signalling molecules in the cardiovascular system
• Natural derived-compounds in controlling redox imbalance in the cardiovascular diseases
• Characterization of mechanism of action of functional foods on cardiovascular diseases
• Pharmacological and nonpharmacological approaches: what is the best way to decrease ROS bioavailability